Total Payments
$123,813
2024 Payments
$2,425
Companies
10
Transactions
137
Medicare Patients
1,469
Medicare Billing
$90,554
Payment Breakdown by Category
Consulting$88,159 (71.2%)
Other$15,150 (12.2%)
Travel$12,185 (9.8%)
Research$5,550 (4.5%)
Food & Beverage$2,769 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $88,159 | 31 | 71.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,150 | 5 | 10.6% |
| Travel and Lodging | $12,185 | 45 | 9.8% |
| Unspecified | $5,550 | 1 | 4.5% |
| Food and Beverage | $2,769 | 54 | 2.2% |
| Honoraria | $2,000 | 1 | 1.6% |
Payments by Type
General
$118,263
136 transactions
Research
$5,550
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $45,186 | 31 | $0 (2023) |
| Merck Sharp & Dohme LLC | $33,397 | 50 | $0 (2023) |
| PFIZER INC. | $26,412 | 17 | $0 (2023) |
| AbbVie, Inc. | $11,246 | 20 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $4,726 | 10 | $0 (2019) |
| Roche Diagnostics Corporation | $2,425 | 1 | $0 (2024) |
| Genentech USA, Inc. | $249.60 | 5 | $0 (2022) |
| EMD Serono, Inc. | $94.38 | 1 | $0 (2022) |
| Dermavant Sciences, Inc. | $41.30 | 1 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $35.61 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,425 | 1 | Roche Diagnostics Corporation ($2,425) |
| 2023 | $9,555 | 8 | PFIZER INC. ($8,269) |
| 2022 | $10,132 | 7 | AstraZeneca Pharmaceuticals LP ($7,260) |
| 2021 | $14,469 | 8 | AstraZeneca Pharmaceuticals LP ($11,344) |
| 2020 | $21,759 | 13 | AstraZeneca Pharmaceuticals LP ($12,175) |
| 2019 | $15,624 | 28 | Merck Sharp & Dohme Corporation ($10,804) |
| 2018 | $27,332 | 35 | Merck Sharp & Dohme Corporation ($10,393) |
| 2017 | $22,517 | 37 | Merck Sharp & Dohme Corporation ($9,916) |
All Payment Transactions
137 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/06/2024 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $2,425.00 | General |
| Category: None | ||||||
| 12/27/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,210.00 | General |
| 10/18/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $41.30 | General |
| Category: DERMATOLOGY | ||||||
| 07/28/2023 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 05/26/2023 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,750.00 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $34.49 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2023 | PFIZER INC. | LORBRENA (Drug) | Travel and Lodging | In-kind items and services | $576.29 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2023 | PFIZER INC. | LORBRENA (Drug) | Travel and Lodging | In-kind items and services | $474.94 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2023 | PFIZER INC. | LORBRENA (Drug) | Travel and Lodging | In-kind items and services | $468.11 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2022 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $94.38 | General |
| Category: Neurology | ||||||
| 06/02/2022 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,420.00 | General |
| Category: Oncology | ||||||
| 05/29/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,025.00 | General |
| 05/26/2022 | Genentech USA, Inc. | Herceptin (Biological) | Food and Beverage | In-kind items and services | $26.98 | General |
| Category: BioOncology | ||||||
| 03/28/2022 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,650.00 | General |
| Category: ONCOLOGY | ||||||
| 03/25/2022 | Genentech USA, Inc. | Herceptin (Biological), Phesgo | Food and Beverage | In-kind items and services | $100.69 | General |
| Category: BioOncology | ||||||
| 03/07/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,815.00 | General |
| Category: Oncology | ||||||
| 12/01/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,117.50 | General |
| Category: Oncology | ||||||
| 10/04/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,420.00 | General |
| Category: Oncology | ||||||
| 06/22/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,815.00 | General |
| Category: Oncology | ||||||
| 06/22/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,815.00 | General |
| Category: Oncology | ||||||
| 06/18/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 06/03/2021 | PFIZER INC. | XALKORI (Drug) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,722.50 | General |
| Category: Oncology | ||||||
| 04/04/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $453.75 | General |
| Category: Oncology | ||||||
| 12/17/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 392 | 784 | $219,245 | $22,102 |
| 2022 | 7 | 462 | 983 | $171,600 | $29,321 |
| 2021 | 8 | 615 | 1,246 | $219,260 | $39,131 |
Total Patients
1,469
Total Services
3,013
Medicare Billing
$90,554
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2023 | 155 | 293 | $65,339 | $8,421 | 12.9% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2023 | 94 | 332 | $88,312 | $7,279 | 8.2% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2023 | 100 | 101 | $35,350 | $2,724 | 7.7% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2023 | 17 | 19 | $20,140 | $2,130 | 10.6% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2023 | 15 | 18 | $6,408 | $1,153 | 18.0% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2023 | 11 | 21 | $3,696 | $395.07 | 10.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2022 | 168 | 434 | $75,950 | $11,809 | 15.5% |
| 88173 | Evaluation of fine needle aspirate with interpretation and report | Facility | 2022 | 52 | 133 | $29,393 | $6,812 | 23.2% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2022 | 43 | 148 | $21,460 | $3,118 | 14.5% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2022 | 22 | 48 | $13,152 | $2,973 | 22.6% |
| 88108 | Cell examination of specimen, concentration technique | Facility | 2022 | 116 | 151 | $15,553 | $2,494 | 16.0% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2022 | 49 | 57 | $12,768 | $1,486 | 11.6% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Facility | 2022 | 12 | 12 | $3,324 | $629.19 | 18.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2021 | 220 | 452 | $79,100 | $12,945 | 16.4% |
| 88173 | Evaluation of fine needle aspirate with interpretation and report | Facility | 2021 | 55 | 149 | $32,929 | $7,946 | 24.1% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2021 | 73 | 246 | $35,670 | $5,388 | 15.1% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2021 | 33 | 82 | $22,468 | $5,215 | 23.2% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2021 | 87 | 116 | $25,984 | $3,135 | 12.1% |
| 88108 | Cell examination of specimen, concentration technique | Facility | 2021 | 109 | 132 | $13,596 | $2,280 | 16.8% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Facility | 2021 | 19 | 19 | $5,263 | $1,190 | 22.6% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2021 | 19 | 50 | $4,250 | $1,031 | 24.3% |
About Dr. Timothy Allen, MD
Dr. Timothy Allen, MD is a Cytopathology healthcare provider based in Galveston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1417945932.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Timothy Allen, MD has received a total of $123,813 in payments from pharmaceutical and medical device companies, with $2,425 received in 2024. These payments were reported across 137 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($88,159).
As a Medicare-enrolled provider, Allen has provided services to 1,469 Medicare beneficiaries, totaling 3,013 services with total Medicare billing of $90,554. Data is available for 3 years (2021–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Cytopathology
- Other Specialties Anatomic Pathology & Clinical Pathology, Anatomic Pathology & Clinical Pathology
- Location Galveston, TX
- Active Since 10/10/2005
- Last Updated 11/22/2024
- Taxonomy Code 207ZC0500X
- Entity Type Individual
- NPI Number 1417945932
Products in Payments
- TAGRISSO (Drug) $20,178
- LORBRENA (Drug) $15,139
- IMFINZI (Drug) $9,253
- XALKORI (Drug) $7,565
- IMFINZI (Biological) $5,445
- OPDIVO (Biological) $4,711
- Herceptin (Biological) $141.49
- Mavenclad (Drug) $94.38
- VTAMA (Drug) $41.30
- DARZALEX (Biological) $35.61
- KEYTRUDA (Biological) $34.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.